1.
Bioorg Med Chem Lett
; 20(15): 4602-6, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20580233
RESUMO
A series of spiro-azetidines and azetidinones has been evaluated as novel blockers of the T-type calcium channel (Ca(V)3.2) which is a new therapeutic target for the potential treatment of both inflammatory and neuropathic pain. Confirmation and optimization of the potency, selectivity and DMPK properties of leads will be described.